![ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business](https://mms.businesswire.com/media/20180914005613/en/678526/5/AJOVY+Image.jpg)
ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business
![Teva Pharmaceuticals on X: "Teva unveils new world class #pharma facility at #Mumbai R&D center: https://t.co/s0LOWejMwH https://t.co/jKjOxoAaGc" / X Teva Pharmaceuticals on X: "Teva unveils new world class #pharma facility at #Mumbai R&D center: https://t.co/s0LOWejMwH https://t.co/jKjOxoAaGc" / X](https://pbs.twimg.com/media/DjDFwiiUUAAgYTs.jpg)
Teva Pharmaceuticals on X: "Teva unveils new world class #pharma facility at #Mumbai R&D center: https://t.co/s0LOWejMwH https://t.co/jKjOxoAaGc" / X
![Teva ponies up $420M to settle with investors who said company hid price-fixing scheme | Fierce Pharma Teva ponies up $420M to settle with investors who said company hid price-fixing scheme | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1642603837/teva1_1.jpg/teva1_1.jpg?VersionId=nO05_Vv2BJv9MBUgDNsNaIO1LnDj7m4Q)